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ABSTRACT 
 
Pain management among pediatric patients with sickle cell disease continues to pose a challenge 
to healthcare providers. Underlying disease processes, family perceptions of painful events, and 
injury add to the complexity of effective pain management in this population. Sickle cell disease 
is the most common variant of the many hemoglobinopathies in the world, with painful episodes 
as the most common presentation to emergency departments for treatment beginning as  
early as 6 to 8 months of age. Sickle cell pain crisis continues to receive less-than-effective pain 
management treatment resulting in frequent hospitalizations, chronic pain, and increased 
morbidity and mortality. This integrative review provides a synthesis of the published evidence 
regarding the best approach to pharmacological management of pain during sickle cell pain crisis 
in the pediatric population. Results of these studies strongly correlate pharmacological pain 
management of pediatric sickle cell crisis pain on consensus and expert opinion with few strong 
research studies conducted to completion. The literature also suggest new knowledge in the areas 
of pathophysiology and pharmacogenomics in provider decisions in pharmacological 
management of pediatric sickle cell crisis pain is not seen in clinical practice resulting in 
undertreatment and repeated hospital admissions. The undertreatment of pediatric sickle cell 
crisis pain contributes to morbidity and early mortality in this patient population.  
Keywords:  pediatrics, sickle cell pain crisis, pain management, pharmacogenomics 
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PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL CRISIS PAIN 
 
Sickle cell disease is an autosomal recessive inherited hemoglobinopathy, which occurs 
in one in every 500 African American births (Raphael, Tran, Mueller, & Giardino, 2013). The 
hallmarks of this disorder are sickling of erythrocytes, occlusion of small blood vessels, and 
pain. These vaso-occlusive painful crises are debilitating and are medical emergencies (Morris et 
al., 2013). Although 78% of 200,000 emergency room visits annually for patients with sickle cell 
disease are for pain, 60% of those visits are among the pediatric population. Children with sickle 
cell disease utilize healthcare services at a rate 8.8 times that of children in general, and have 
increased hospitalizations and longer hospital stays than children with other chronic illnesses, 
with an estimated average healthcare cost of approximately $1,354,000 during childhood (ages 
0-21) (Raphael et al., 2013).  
Many advances in the treatment of sickle cell disease have extended the life expectancy 
from early childhood/young adulthood in the period 1950-1980, to a more recent range of 50 to 
70 years in high-income countries such as the United States (Ballas, 2014). Sickle cell disease is 
multifaceted, including neurological compromise, acute chest syndrome, sickle cell crisis pain, 
and organ damage. Sickle cell crisis pain accounts for approximately 70% of all emergency 
department visits for children with sickle cell disease (Fein, Avner, Scharbach, Manwani, & 
Khine, 2017). Treatment of pediatric sickle cell pain crisis remains an area experiencing minimal 
improvement toward effective management. Healthcare providers are beginning to research areas 
of pain management utilizing a multimodal model to address the effective relief, intensity, and 
frequency of pain symptoms among the pediatric population.  
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This integrative review will provide a discussion of published literature related to 
evidence-based pharmacological pain management strategies in the hospital setting for the 
pediatric sickle cell patient experiencing a pain crisis. This review will contribute to the practice 
of pain management of the pediatric sickle cell patient in pain crisis for the advance practice 
nurse with improvement in the relief, intensity, and frequency of pediatric sickle cell pain crisis. 
The focus of this integrative review is to analyze and synthesize the literature to present 
evidence-based approaches to pharmacological management of pain during sickle cell pain crisis 
in the hospitalized pediatric population.  
Background 
 
Pain and Pediatric Sickle Cell Disease 
 
Understanding the mechanisms of pain in the sickle cell patient directs the effective 
treatment and research into new treatment regimens in the relief of pain, decrease in pain 
intensity, and pain frequency resulting in hospitalizations. Sickle cell pain crisis is defined by the 
different types of pain and area of the nervous system impacted. Intermittent vaso-occlusive pain 
crisis, defined by the lack of pain between episodes, is most common among the pediatric sickle 
cell population. Because the dorsal horn is the main pathway to the central nervous system, 
inhibiting and minimizing the transmission of painful stimuli begin here with pain relief efforts 
by endogenous endorphins (Ballas, 2014). The second step is to control the transmission of 
painful stimuli through the two sodium channel receptors, which determine the type, severity, 
and duration of the vaso-occlusive pain crisis. These sodium channels, a-Amino-3-hydroxy-
5methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-Daspartic acid (NMDA) channels, 
allow for effective relief of pain with non-opioids and opioids unless aberrant metabolism of 
opioids exists for intermittent vaso-occlusive pain crisis (Ballas, 2014).  
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Pain and Pharmacogenomics in Sickle Cell Disease 
 
Pharmacogenomics has become a new field of research for improvement in pain 
management among pediatric sickle cell pain crises. Understanding of the metabolic pathway 
will assist healthcare practitioners in the development of individualized pain management 
treatment plans to correct the undertreatment of pediatric sickle cell pain crisis. Traditionally 
nonsteroidal anti-inflammatory drugs (NSAID) and opioids are the backbone of pain 
management in children with sickle cell disease (Jaja, Patel, Scott, Gibson, & Kutlar, 2014; Yee 
et al., 2013). Many African Americans and those of African descent are affected by genetic 
variations in the CYP2D6 gene, which may contribute to poor metabolizing of opioid 
medications requiring this pathway in obtaining pain relief (Yee et al., 2013). According to Jaja 
et al. (2014), African American children with sickle cell disease have a slightly higher frequency 
of the CYP2D6 gene deletions compared to healthy African Americans. Many pediatric patients 
experience adverse reactions of narcotic administration, such as respiratory depression and 
euphoria, without any analgesic effect (Yee et al., 2013). Notably, the CYP2C9 allelic variant 
study showed 30% of children with at least one allele associated with reduced function in 
metabolizing NSAIDS resulted in decreased analgesic effect and increased toxicity (Jaja et al., 
2014). Impaired NSAID metabolism is strongly associated with the following adverse effects 
among children with sickle cell disease treated for sickle cell crisis pain: gastrointestinal 
complications, renal impairment, fluid retention, and exacerbation of asthma (Jaja et al., 2014). 
Understanding the metabolic pathway of the most commonly used medications in the treatment 
of pediatric sickle cell crisis pain could potentially enable clinicians to identify patients with 
impaired CYP2C9 metabolic capacity, enabling clinicians to make distinctions between a 
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compliance problem and a metabolic defect, and tailor NSAID dosing accordingly to achieve 
optimal analgesic response (Jaja et al., 2014). 
At this time feasibility of genetic testing is not available; therefore, clinicians must use 
clinical signs and symptoms of failed opioid and NSAID treatment of sickle cell pain crisis and 
seek other adjuvants to obtain pain relief and decrease in pain intensity and pain frequency. 
 
Figure 1. Effects of gene deletions and allelic variants in the opioid and NSAID metabolic 
pathways. Adapted from Yee et al., 2013; Jaja et al., 2014. 
Pharmacological Pain Management and Sickle Cell Pain Guidelines 
 
Opioid metabolic 
pathway CYP2D6 
African American children with sickle 
cell disease have a slightly higher 
frequency of gene deletions. 
Morphine clearan e is significantly 
higher in individuals with sickle cell 
disease compared to non-sickle cell 
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May experience adverse reactions of 
narcotic administration without 
analgesic effect 
NSAID metabolic 
pathway CYP2C9 
30% of children with at least one allel 
associated with reduced function in 
metabolizing NSAIDS 
Reduced function in metabolizing 
NSAIDs results in decreased analgesic 
effect and increased toxicity. 
The following are NSAID adverse 
effects among children with sickle 
cell disease treated for sickle cell 
crisis pain: gastrointestinal 
complications, renal impairment, 
fluid retention, and exacerbation of 
asthma.  
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Many of the recommendations are based on weak evidence or recommendations related 
to expert opinion, consensus, and studies from pain in children with cancer (National Heart, 
Lung, and Blood Institute, 2014; World Health Organization, 2012). The World Health 
Organization (WHO) guidelines use a 2-step approach to address pain in children with medical 
illnesses based on strong recommendation with low quality of evidence (World Health 
Organization, 2012). According to WHO, the first step is the treatment of mild pain with 
paracetamol and ibuprofen. The second step is the treatment of moderate to severe pain utilizing 
opioids, with morphine as the drug of choice. The WHO guidelines of 2012 do not recommend 
the use of steroids in the treatment of pediatric sickle cell crisis pain or tramadol, due to a lack of 
available evidence of effectiveness and safe use in children (World Health Organization, 2012). 
These guidelines are not specific to sickle cell crisis pain but address this patient population in 
the discussion. According to Sheely (2015), treatment of sickle cell crisis pain has poor levels of 
evidence based on observational studies and expert opinion rather than clinical trials (Sheehy, 
Finkle, Darbari, Guerrera, & Quezado, 2015). A multicenter research study has been undertaken 
with a focus on the mechanism of sickle cell crisis pain with intravenous magnesium, as have a 
few studies with oral magnesium to address the pathophysiology of sickle cell crisis pain in the 
prevention of pain instead of treating sickle cell crisis pain in children (Badaki-Makun et al., 
2014). 
Pharmacological Pain Management and Sickle Cell Pain Research Trials 
 
The majority of pain research has been among cancer patients and adults. Gaps exist in 
the literature on pain research specific to pediatric sickle cell patients. Effective management of 
sickle cell crisis pain in children in the emergency department and hospital setting utilizes three 
major classes of medications: opioids, non-opioids, and adjuvants (Hagedorn & Monico, 2016). 
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Much of the research has focused on narcotic sparing interventions such as arginine, which is a 
substrate of nitrous oxide production. Arginine is considered safe, inexpensive, and narcotic 
sparing, which is important in the treatment of children with concerns for opioid metabolism as 
an adjuvant in the treatment of pediatric pain crisis (Morris et al., 2013). Pain management 
treatment for sickle cell patients who have failed typical pain management with opioids utilizes 
ketamine, intranasal fentanyl, dexmedetomidine, gabapentin, and methadone for its analgesic 
effect among the pediatric population. Ketamine infusion is viewed as an effective adjuvant in 
the hospital setting in treating pediatric sickle cell pain and the safe monitoring and treatment of 
any adverse reactions to this medication (Hagedorn & Monico, 2016). 
Problem Statement 
 
Noted as an accepted world health concern with associated morbidity and mortality, the 
treatment of pediatric sickle cell pain crisis needs to be addressed among healthcare practitioners. 
Improving quality of life, enhancing life expectancy, obtaining pain relief, and decreasing pain 
intensity and frequency resulting in fewer emergency department visits and decreased length of 
stay all outline the multimodal dynamics of pediatric sickle cell pain crisis. Pediatric sickle cell 
pain crisis pain management continues to be undertreated and difficult to treat. According to 
Ender et al. (2014), patients who reported high pain scores in sickle cell crisis pain historically 
have increased risk of early death compared to patients who reported the lowest pain scores. 
Improvement in the management of sickle cell crisis pain may help prevent hospitalizations, 
morbidity, and mortality associated with sickle cell disease pain (Cacciotti, Vaiselbuh, & 
Romanos-Sirakis, 2017; Lin, Strouse, Whiteman, Anders, & Stewart, 2016). 
Purpose and Significance of the Scholarly Project 
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The purpose of this scholarly project is to present evidenced-based pharmacological pain 
management strategies in the care of sickle cell pain crisis within the pediatric population. The 
management of pediatric sickle cell involves an understanding of its pathophysiology and 
available treatment methodology available to healthcare providers. These strategies will advance 
the practice of nursing in providing supportive care and symptom management, and improving 
quality of life and life expectancy for children diagnosed with one of the world’s largest 
hemoglobinopathies. 
Sickle cell disease is the most common genetic hematological disorder in the United 
States (U.S.). One in every 375 African-Americans is affected by sickle cell disease, with U.S. 
estimates of 72,000 to 98,000 when corrected for early mortality (Lin et al., 2016). The leading 
causes of mortality among people with the diagnosis of sickle cell disease include bacterial 
infections from encapsulated organisms (38.4%), cerebral vascular accident (12.3%) with acute 
pain crisis, and acute chest syndrome at 11%, with sickle cell pain crisis as the most common 
presenting complication of this disease (Lin et al., 2016). Sickle cell pain crisis is associated with 
increased risk of acute chest syndrome and mortality; thus, improvement in pain management 
among children with sickle cell disease could help decrease acute chest syndrome and mortality 
from sickle cell disease. The need exists for healthcare providers to do the following: 
1. Understand the mechanism of sickle cell crisis pain, and the impact of undertreatment 
of pediatric sickle cell pain crisis. 
2. Provide evidence-based and expert opinion in the development of pain management 
strategies and guidelines. 
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Figure 2.  Leading causes of mortality in sickle cell disease (Lin et al., 2016). 
Clinical Questions 
 
This integrative review will address the following clinical question: What is the best 
pharmacological approach in the management of sickle cell pain crisis in the hospitalized 
pediatric patient? 
Questions to support and maintain focus of this review: 
1. What evidence-based pain management strategies have been found to be safe and 
effective in the management of sickle cell pain crisis in the hospitalized pediatric patient? 
2. What best practices in pharmacological management support safe and effective treatment 
of pediatric sickle cell crisis pain? 
The goals of this project will be: 
1. To provide a systematic integrative review of the literature related to pharmacological 
pain management of pediatric sickle cell pain crisis. 
2. To provide recommendations for the treatment of pain in the hospitalized pediatric sickle 
cell pain crisis patient. 
Leading causes of mortality in sickle cell 
disease 
Bacterial infections Cerebral vascular accident
Acute chest syndrome Sickle cell crisis pain
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Methods 
 
Scientific reviews influence the definition of knowledge and clinical practice within the 
healthcare environment. The conceptual framework developed by Harris Cooper (1982) was the 
methodology used for this integrative review providing the rigor and validity needed in the 
synthesis of evidence related to pharmacological pain management of pediatric sickle cell pain 
crisis. This framework enables the project leader to provide evidence-based research findings, 
guidelines, and reviews to healthcare practitioners in a concise report that highlights any bias, 
limitations, need of further research, and practice implications (Cooper, 1982). An integrative 
review is performed to explore the use of pharmacological treatment of sickle cell crisis pain 
among children with sickle cell disease. The Liberty University Institutional Review Board 
(IRB) application number 3189 was approved (see appendix D for approval letter). The focus of 
this integrative review is to summarize past guidelines, reviews, and research of pharmacological 
treatment of children with sickle cell crisis pain, presenting a current state of knowledge. 
Framework 
 
The framework for this scholarly project is rooted in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) statement for reporting systematic reviews 
and meta-analysis of studies that evaluate health care interventions (Liberati et al., 2009). The 
foundational framework for the scholarly project is defined by Harris Cooper (1982). In addition, 
the tool used for analyzing the literature is from the guidelines of Melnyk and Fineout-Overholt 
(2011) for critiquing evidence. 
PRISMA Statement 
 
The purpose of the PRISMA system is to provide essential tools needed for summarizing 
evidence accurately and reliably to assess the risk and benefits of a healthcare intervention. The 
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PRISMA statement embraces a 27-item checklist and a four-phase flow diagram consisting of 
identification, screening, eligibility, and inclusion of retrieved literature to provide consistency in 
the process and documentation of reviews across all healthcare disciplines (see Appendix A for 
PRISMA flow diagram). The essential items for reporting were based on the 27-item checklist to 
ensure transparent reporting of systematic reviews, reducing the risk of flawed reporting of 
systematic reviews. 
Melnyk and Fineout-Overholt Critiquing Evidence 
  
        The tool used for analyzing the literature is from Melnyk and Fineout-Overholt’s (2011) 
guidelines for critiquing evidence (Appendix C). The concept presented has a focus on viewing 
the research for the contribution it can make to practice, instead of looking for study flaws in 
determining inclusion as evidence during the appraisal process (Fineout-Overholt, Melnyk, & 
Schultz, 2005).  According to Fineout-Overholt, Melnyk, and Schultz (2005),  
The purpose of critical appraisal is to determine the value of the research to practice by 
answering the following questions: (1) Are the results of the study or systematic review 
valid? (2) What are the results? (3) Are the findings clinically relevant to my practice? (p. 
339)  
The guideline discusses seven levels of evidence, with level 1 as the most rigorous, including 
systematic reviews, randomized controlled trials, and guidelines based on systematic reviews or 
meta-analysis, to level 7 for expert opinion. Case studies, cohorts, and qualitative studies are 
described in the level of evidence table. An algorithm is used to guide the literature-critiquing 
process, utilizing a step-wise flow to determine the level of evidence. 
Cooper 
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This scholarly activity is a rigorous process used to synthesize separate evidence-based 
findings into a coherent whole (Cooper, 1982), providing a summary of the accumulated 
scientific knowledge concerning the pharmacological treatment of sickle cell crisis pain, bringing 
to the forefront research that was left unresolved. There are five phases to the integrative review 
process: problem formation, data collection, evaluation of data points, data analysis and 
interpretation, and presentation of results (Cooper, 1982). Each phase of the process addresses 
threats to validity and ways to protect from threats to validity, enabling the project leader to 
make fine distinctions between research study and review-based inferences providing optimal 
criteria as practice guidelines. This process outlined by project leaders was closely followed to 
decrease bias and inaccuracy, and to maintain academic rigor. 
Problem Formulation Stage 
 
        This stage defines parameters and focus for the review process, clearly identifying the 
problem and defining variables of interest. The problem addressed in this integrative review of 
the literature is the best pharmacological approach in the management of pain during sickle cell 
pain crisis in the pediatric population. Points of interest for the project include currently available 
guidelines for pediatric sickle cell pain crisis, relevant pharmacological research in treatment of 
pediatric sickle cell pain crisis, and factors contributing to the paucity of completed research 
among children with sickle cell pain crisis. Other considerations of interest include factors 
contributing to adherence or non-adherence to guidelines or protocols. According to Ballas 
(2014), although there are many advances in the treatment of sickle cell disease, minimal 
advances are noted in the management of pediatric sickle cell pain crisis. The World Health 
Organization (WHO, 2012) and the National Heart, Lung, Blood Institute (NHLBI, 2014) reports 
identified early initiation of analgesics in the relief of pain symptoms. Many of the guidelines are 
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based on consensus and expert opinion due to the limiting factor of incomplete research trials 
related to patients presenting in distress, hindering their ability to give consent/assent, according 
to Nottage et al. (2016).  
Data Collection Phase 
 
The data collection stage of the review process involves identifying the population of 
interest and relevant elements of inquiry (Cooper, 1982). The project leader has recognized that 
one threat to validity is associated with retrieved studies not including all studies pertinent to the 
topic of interest, the pharmacological pain management of sickle cell pain crisis in children. 
Nevertheless, the project leader has utilized the online information retrieval technique, using key 
words and phrases to obtain the maximum number of eligible studies. 
Information Sources 
 
Bibliographic databases, ancestry approach, and the Science of Social Science Citation 
Indexes strategies were employed. The bibliographic search was performed using a 
comprehensive, computer-assisted online search of EBSCO host, the Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), ProQuest, and Medline databases. The search 
included dates from January 2012 to December 2017. The ancestry and Science of Social Science 
Citation Indexes strategies were used to identify key studies within the search criteria dates. Key 
terms used for the search include pediatric, sickle cell pain crisis, and pain management. 
Boolean operators were used to refine and help focus the search (Holly, Salmond, & Saimbert, 
2017). To determine the adequacy of the literature search strategies and to refine skills of the 
project leader, a professional librarian was consulted. 
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Eligibility Criteria 
 
Defining eligibility criteria of the patient population, inclusion, and exclusion criteria 
guided the data collection phase of this review. The pediatric patient population is defined as 0 
years to 21 years, which will allow for generalizations among pediatric patients with sickle cell 
pain crisis. The search of the literature included publications from January 1, 2012 to December 
11, 2017, to obtain the most recent research and assess for areas of further inquiry. Criteria for 
using publications included pharmacological intervention subject matter, full-text availability, 
English-language reports, and U.S.-based research trials. Eligibility criteria for data collection 
was supported by inclusion and exclusion criteria found in Table 2.   
Literature Search Results 
 
        Utilizing EBSCO host, the Cumulative Index of Nursing and Allied Health Literature 
(CINAHL), ProQuest, and Medline databases with inclusion dates from January 2012 to 
December 2017, the search results identified 1,565 studies, guidelines, and reviews with no other 
studies from other sources identified using the following key words: pediatrics, sickle cell pain 
crisis, pain management. Of the 1,565 articles, 489 were duplicates. During the screening 
process, the researcher reviewed summaries for the 1,076 studies, guidelines, and reviews 
remaining after duplicates were extracted. Further review excluded 1,020 studies not meeting 
established inclusion criteria, leaving 56 full-text studies to assess for eligibility. Continued 
assessment resulted in the exclusion of 35 additional studies based on pre-set inclusion criteria, 
leaving 21 studies, reviews, and guidelines for critical review. The critique and analysis of the 21 
publications will be available in Tables 2-5.  
Data Evaluation Stage 
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During the data evaluation stage, data in the literature meeting criteria will undergo 
critical judgment by the reviewer (Cooper, 1982). Primary and secondary sources were examined 
and a determination made to evaluate if multifactorial contamination irrelevant to the problem of 
interest had occurred (Cooper, 1982). Evaluation criteria were developed by the reviewer prior to 
beginning the literature search, and only one reviewer was utilized during this process. 
Data Analysis Stage 
 
This stage of the integrative review process incorporated the synthesizing of the evidence 
into a coherent statement about the research question (Cooper, 1982). A matrix in a table format 
was used to organize, categorize, and summarize data according to the project clinical focus (see 
Tables 2-5). The Nursing: Melnyk Pyramid (2011) I-VII leveling system was utilized in the 
evaluation and analysis of the data sources (see Appendix C for Melnyk Pyramid). The sources’ 
theoretical information (pharmacological management of pediatric sickle cell crisis pain); 
evaluation information including level of evidence and source; and methodological data (sample 
size and setting) support for specific clinical questions were documented across studies 
consistently. Records were kept during the data analysis process to ensure analytical integrity.  
Data reduction. The reduction phase, which identified data according to subgroups to 
promote effective management and maintain methodological rigor with the clinical question 
guiding the focus, was performed in two sub-phases. First, subgroups classifications based on 
level of evidenced were analyzed. The second sub-phase of reduction involved organization of 
the extracted data into a manageable framework for display. 
Data display. The extracted data were displayed within three matrices. Each matrix 
represented an enhanced visualization of patterns across all data sources. In a visual format, each 
matrix provides an organized record of relevant results for the literature (Holly et al., 2017). 
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Data comparison. During the data comparison step of the integrative review patterns, 
themes and relationships in the literature were identified. Diagrams displaying this visual 
concept of the extracted data provided a visual systematic critical analysis and meaning of the 
review findings. This visual diagram made the depiction of relationships, patterns, and themes 
easier to capture. 
Conclusion drawing and verification. According to Holly et al. (2017), findings from 
the literature serve as data and appear as themes, metaphors, and key concepts that are developed 
into succinct summaries of the findings. As commonalities and differences become apparent and 
identified generalizations are formed, constructing a new comprehensive depiction of the subject 
matter integrating all subgroups occurs during this process. Cooper (1982) stated the value of a 
quantitative integrative review as follows: “The question is still open, and both sides will 
probably revise their position before the debate is over” (p. 298). 
Presentation of Results 
 
Cooper (1982) described the translation of notes, printouts, and remembrances into a 
public document as the presentation of the inquirer’s efforts to disseminate accumulated 
knowledge to the scientific community. Data form the literature sources meeting inclusion 
criteria were displayed and organized for ease of reader access to data points. To accomplish this 
task, the DNP graduate employed the use of concept diagrams, tables, and flowcharts 
accompanied by a narrative of the results. Tables were organized including level of evidence, 
source, focus of literature source, conclusions, implication for practice, and recommendations. 
Concept diagrams were used to illustrate the major themes, patterns, relationships, and 
recommendations identified.  
Evaluation Methods 
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Results 
 
There were 21 quantitative research articles included in the integrative review (see Table  
1). The types of design included the following: two level-1 systematic reviews of randomized 
control trials (Badaki-Makun et al., 2014; Brandow et al., 2016); seven level-2 randomized 
control trials (Brousseau et al., 2015; Fein et al., 2017; Horst, Frei-Jones, Deych, & Shannon, 
2016; Morris et al., 2013; Nottage et al., 2016; Jaja et al., 2014; Yee et al., 2013); one level-3 
controlled trial with no randomization (Ender et al., 2014); three level-5  systematic reviews of 
descriptive studies (Ballas, 2014; Hagedorn & Monico, 2016; Neri, Pestieau, & Darbari, 2013); 
six level-6 descriptive observational designs (Cacciotti et al., 2017; Krishnamurti et al., 2014; 
Lin et al., 2016; Raphael et al., 2013; Sheehy et al., 2015; Sheehy et al., 2017) and two level-7 
expert opinions (National Heart, Lung, and Blood Institute, 2014; World Health Organization, 
2012). Results of the integrative review receive further discussion using descriptive narratives 
and diagrams of significant concepts. 
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Pain and Pediatric Sickle Cell Disease 
 
What should healthcare providers understand about the mechanism of sickle cell crisis 
pain?  
        Four of the 21 studies discussed the mechanism, pathophysiology, and pharmacogenomics 
of sickle cell crisis pain (Ballas, 2014; Jaja et al., 2014; Raphael et al., 2013; Yee et al., 2013). 
These articles focus on two major pain pathways in the treatment of sickle cell crisis pain. The 
first pathway allows travel of the pain stimuli to the central nervous system while sodium 
channel receptors determine the type, intensity, and duration of sickle cell crisis pain. Healthcare 
providers treating sickle cell crisis pain should administer parental opioid with frequent 
reassessment of pain relief. Upon further evaluation of pain symptoms, combination therapy of 
NSAIDS and adjuvants may be necessary, understanding the presence of hyperalgesia and 
allodynia are symptoms of neuropathic pain. Informed clinicians are equipped to recognize 
medication failure as a genetic variant and metabolic deficiency of ineffective pain management 
and to administer effective medication and dosage in treating children with sickle cell crisis pain.  
When considering pharmacological treatment of sickle cell crisis pain, opioids and 
NSAIDs remain the backbone of treating pediatric sickle cell crisis pain in the hospital setting. 
The field of pharmacogenomics assists the healthcare provider in identifying patients with 
genetic variations of the CYP2D6 and CYP2C9 pathways contributing to poor pain response and 
repeated failed emergency department management of pediatric sickle cell crisis pain. Among 
African Americans, genetic variants of the CYP2D6 pathway for opioid metabolism are higher 
among those with sickle cell disease. Healthcare providers should be aware that 30% of children 
with sickle cell disease may also have a CYP2C9 genetic variant decreasing the analgesic effect 
of NSAIDs, with an increase in adverse reactions. Understanding of the pathophysiologic 
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mechanism and pharmacogenomics of management of children experiencing sickle cell crisis 
pain has improved, although clinical management of sickle crisis pain does not reflect new 
knowledge.  
 
 
Figure 3. Flowchart of pain and pediatric sickle disease theme. Adapted from Ballas, 2014; 
Nottage et all. 2016; Raphael, Tran, Mueller, and Giardino, 2013; Yee et al., 2013. 
Pain Management and Pediatric Sickle Cell Pain Guidelines 
 
What are the currently available guidelines in the treatment of pediatric sickle cell pain 
crisis and barriers to healthcare providers?  
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Four of the 21 studies discussed guidelines for the treatment of pain management of pain 
in children with medical illnesses, sickle cell crisis pain, definitive reference for the use of 
ketamine infusion, and developing clinical pathways in the treatment of children with sickle 
crisis pain (Ender et al., 2014; Hagedorn & Monico, 2016; National Heart, Lung, Blood Institute, 
2014; World Health Organization, 2012). These guidelines address time to initial dose of 
medication, opioids as the drug of choice, reassessment intervals, incorporation of technology, 
and intercollaborative teams. The nhlbi digital resource obtained data for a report based on 
consensus from the American Pain Society. Of the nine pharmacological recommendations, only 
one had high quality evidence and strong recommendation for rapid initiation of parental opioids 
for the treatment of sickle cell crisis pain; two had low quality for treatment with NSAIDS for 
mild pain if not contraindicated. The WHO developed a two-step approach in the pain 
management of pain in children with medical illnesses, after removing codeine from the 
analgesic ladder related to many poor metabolizers resulting in the ineffectiveness of pain relief 
or ultra-metabolizers resulting in toxicity. This approach recommends NSAIDs for mild pain as 
the first step, progressing to low-dose morphine for moderate pain, and increasing to standard 
dosing of morphine for severe pain. The WHO standard of pain assessment is, upon arrival at 
emergency department with administration of parental opioid, with 30 minutes of triage or 60 
minutes of registration, and with subsequent pain assessment at 15-30-minute intervals until pain 
is controlled, as reported by the patient. All the guidelines and reviews agree that morphine is an 
essential medication in the treatment of sickle cell crisis pain. In patients with repeated failed 
pain relief with opioids and NSAIDs, the addition of non-opioids and adjuvant may significantly 
decrease pain scores.  
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Managing pediatric sickle cell crisis pain is resource and time intensive. Only 9% of 
pediatric-trained and 20% of adult-trained pediatric emergency department physicians report 
following institutional protocols when treating sickle cell crisis pain (Cacciotti et al., 2017). 
Many physicians cite two factors causing delays in the treatment of pediatric sickle cell crisis 
pain:   
1. Time required in reviewing patient chart;   
2. Deciding the optimal pain management regimen.  
No universal pediatric emergency department analgesic guidelines exist for the treatment of 
sickle cell crisis pain (Cacciotti et al., 2017). The development of multidisciplinary clinical 
pathways may promote the use of new knowledge in the clinical setting. 
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Figure 4. Flowchart of pediatric sickle cell crisis pain guideline themes. Adapted from Ender et 
al., 2014; Hagedorn and Monico, 2016; National Heart, Lung, and Blood Institute, 2014; World 
Health Organization, 2012. 
Pain Management and Pediatric Sickle Cell Pain Research Trials 
 
What identified evidence-based pain management strategies are found to be safe and 
effective in the hospitalized pediatric sickle cell patients in pain crisis?  
Prior research generally confirms morphine as the drug of choice in the initial treatment 
of sickle cell crisis pain. Current research favors combination therapy of opioids and non-
Pediatric Sickle Cell Crisis Pain 
Guidelines and Review 
WHO 2-step analgesic ladder 
-Parental opioids as drug of choice 
for initial treatment 
-Use of non-opioids and adjuvants 
with failed response to opioids 
-New knowledge of pain 
management not used in clinical 
practice 
-Patient chart review and decision-
making barriers to increase time to 
initial medication administration 
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steroidal medication after an initial dose of parental opioids (Badaki-Makun et al., 2014; 
Brandow et al., 2016; Brousseau et al., 2015; Cacciotti et al., 2017; Fein et al., 2017; Horst et al., 
2016; Morris et al., 2013; Neri et al., 2013; Nottage et al., 2016; Sheehy et al., 2015; Sheehy et 
al., 2017). Since sickle cell crisis pain encompasses inflammatory, infarction, tissue damage, and 
neuropathic pain, the combination therapy of opioids, NSAIDs, and adjuvants is used to optimize 
pain management. 
Further studies are entertaining combination therapies utilizing pathophysiology of sickle 
cell crisis pain and receptors, reducing opioid tolerance and opioid induced hyperalgesia. 
Medications not dependent on CYP2D6 pathways are needed for repeat failed opioid therapy 
when aberrant genetics are present. Adjuvants such as arginine, ketamine, gabapentin, fentanyl, 
dexmedetomidine, methadone, and magnesium are thought to be opioid reducing and safe in the 
hospital setting, providing analgesia in the brain and spinal cord. The route of medication 
administration affects the time to initial medication, and thus intranasal and subcutaneous routes 
are explored since intravenous access poses a delay in beginning treatment. 
What factors contribute to the paucity of literature in the treatment of pediatric sickle cell 
pain crisis?  
Much of the research in surrounding pediatric sickle cell crisis pain is hindered by the 
inability to obtain adequate sample size to conduct research with generalizable results. The most 
common limiting factor in completing research trials among this population relates to patients 
presenting to the emergency department in distress, hindering their ability to give consent/assent. 
Many research designs are shifting to obtaining consent/assent during routine clinic visits, in 
order to increase participation for outcome analysis and clinical relevance.  
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Figure 5. Flowchart of pediatric sickle cell crisis pain disease research themes. Adapted from 
Badaki-Makun et al., 2014; Brandow et al., 2016; Brousseau et al., 2015; Cacciotti et al., 2017; 
Fein et al., 2017; Horst et al., 2016; Morris et al., 2013; Neri et al., 2013; Nottage et al., 2016; 
Sheehy et al., 2015; Sheehy et al., 2017. 
Synthesis of Results 
 
The many advances in the care of sickle cell disease have brought only minimal 
improvements in the treatment of sickle cell crisis pain. The strength of the evidence was on both 
Pediatric Sickle Cell Crisis Pain 
Research 
*treat inflammation, infarction, and 
tissue damage 
*Opioids drug of choice 
*combination therapy opioids and 
non-steroidal 
*intranasal and subcutaneous 
medication routes obtain 
consents/assent for research trials 
during routine clinic visits 
*utilization of pathways not dependent 
on CYP2D6 
*include neuropathic medications as 
adjuvants 
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ends of the spectrum, with 12 studies on the high end and nine on the moderate-to-low end on 
the Nursing: Melnyk Pyramid with a leveling system of I-VII. Three of the studies were reviews 
of one multicenter trial on magnesium in the treatment of sickle cell crisis pain with the potential 
to alter the pathophysiology of pain crisis. Many of the studies specific to pediatric sickle cell 
crisis pain had small sample sizes, closed, or were still in progress after two years seeking to 
obtain participants to continue the study. Many studies had small sample sizes and multicenter 
studies were few. Results of these studies strongly correlate patient reports of sickle cell crisis 
pain severity with increased risk of mortality. Many of the reviews are based on studies 
conducted within cancer treatment of pain and perioperative pain management disciplines. Sickle 
cell crisis pain is multidimensional and complex, including inflammatory, infarction, and tissue 
damage with a profound effect on morbidity and mortality in the pediatric population. Three 
major classes of medications—opioids, non-opioids, and adjuvants—are effectively used in the 
treatment of pediatric sickle cell crisis pain. 
 
Figure 6. Flowchart of classes of safe and effective medications. Adapted from Hagedorn and 
Monico, 2016. 
Pediatric sickle cell crisis pain research continues to depend on consensus and expert 
opinion with few strong research studies conducted to completion. The need to develop research 
•morphine,fentanyl 
•hydromorphine Opioids 
•nonsteriodal, anti-inflammatories 
•acetaminophen,tramadol Non-opioids 
•antidepressants,benzodiazepines 
•antihistamines,anticonvulsants Adjuvants 
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protocols that remove barriers to conducting research to completion are drastically needed. The 
lack of clinical guidelines utilizing new knowledge of the pathophysiology and 
pharmacogenomics of sickle cell crisis pain has resulted in readmission of patients presenting 
with the most common symptom of sickle cell disease.   
Development of comprehensive emergency department guidelines with the participation 
of pain management, anesthesia, pharmacy, and nursing may contribute to optimal and consistent 
care (Badaki-Makun et al., 2014; Cacciotti et al., 2017).  
Discussion 
 
Summary of the Evidence 
 
Research revealed the treatment of pediatric sickle cell crisis guidelines are based on few 
evidenced-based studies with strong to moderate recommendations based on consensus and 
expert opinion (National Heart, Lung, and Blood Institute, 2014; World Health Organization, 
2012). The goal of this integrative review was to identify strong evidence-based studies in the 
pharmacological treatment of pediatric sickle cell crisis pain to bring new knowledge to clinical 
practice although there was strong consensus the research trials lacked sufficient numbers to 
apply to the general population. Many of the studies addressed the clinical question but lacked 
the rigor necessary to address pediatric sickle cell crisis pain management in a generalizable 
setting. Two of the studies discussed developing clinical pathways and individual treatment plans 
utilizing interdisciplinary teams and resource nurses to address the multifactorial needs of this 
patient population, with the understanding that only 9% of pediatric-trained and 20% of adult-
trained emergency department healthcare providers utilize these important tools in improving 
patient outcomes (Cacciotti et al., 2017; Ender et al., 2014; Krishnamurti et al., 2014). Although 
the 21 studies addressed pharmacological management of sickle cell crisis pain, three studies 
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included new knowledge from pathophysiology and pharmacogenomics in their studies 
(Brousseau et al., 2015; Jaja et al., 2014; Neri et al., 2013). Since mechanism-based strategies for 
treating sickle cell crisis pain are sorely lacking, healthcare providers are reduced to treating the 
symptom of pain (Sheehy et al., 2015). 
Limitations 
 
According to Cooper (1982), the five stages in the integrative review process are to 
provide rigor and address threats in the review (Cooper, 1982). External bias of the studies 
related to small sample size and single institution subjects was observed. Since inclusion criteria 
were limited to U.S. studies, the strength of the evidence with combined studies was lacking. 
Another limiting factor during the data evaluation stage was the use of one reviewer, who was 
also the project leader. 
Additional research is needed with larger sample sizes and multicenter involvement to 
address the treatment of sickle cell crisis pain utilizing pathophysiology and pharmacogenomics 
in the process. Research teams need to be more interdisciplinary and intercollaborative, including 
all stakeholders to address this most debilitating problem in the lives of children with sickle cell 
disease. The development of practice guidelines in other medical conditions has improved 
clinical outcomes and patient satisfaction. This is an opportunity to build upon nursing science, 
policy development, and applying new knowledge into clinical practice. 
Conclusion 
 
        The undertreatment of sickle cell crisis pain is well known among healthcare providers 
caring for children with sickle cell disease. The increased cost, hospitalizations, missed school 
days, and decrease in life expectancy are not an option in the 21st-century healthcare 
environment. This integrative review seeks to raise awareness of the old but continuing saga of 
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undertreated pediatric sickle cell crisis pain and its effect on society, and its global impact. 
Historically, patients who report high pain scores had increased risk of early death compared to 
patients who report lower scores. Sickle cell disease is the most common of all inherited 
hemoglobinopathies, with an average healthcare cost of $1,354,000 during childhood (ages 1-
21). Clinical pathways for other pediatric diseases promote rapid stabilization, reduced hospital 
admission rates, reduced inappropriate therapies and should be considered in addressing the 
undertreatment of pediatric sickle cell crisis pain.  Healthcare providers are in a position to affect 
policy and practice changes to support clinical guidelines and research opportunities to address 
this age-old concern. How long must children with sickle cell disease suffer from sickle cell 
crisis pain? Healthcare providers must answer with a unanimous voice: “Not long.” 
Implications for Practice 
 
The most common presenting symptom of sickle cell disease to the emergency 
department is sickle cell crisis pain in children, and it remains the most resource- and cost-
intensive medical illness. There is a great need to develop guidelines to decrease pain frequency 
and intensity based on high quality evidence-based research. The addition of information 
technology with the ability to create reminders in medication administration to assist providers in 
busy emergency departments and to allow easy access to protocols to facilitate decision making 
regarding treatment regimens is desperately needed. Enhancing healthcare providers’ knowledge 
of effective treatment strategies and new knowledge from pathophysiology and 
pharmacogenomics is paramount in the care of children experiencing sickle cell crisis pain. The 
development of point-of-care genomic testing for individuals with repeated pharmacological 
failures is a valuable tool to direct effective evidence-based pain management in this patient 
population. 
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Research supports the use of opioids, non-opioids, non-steroidal pain relievers and 
adjuvants in the treatment of sickle cell crisis pain with the introduction of intranasal and 
subcutaneous routes when there is a delay in obtaining intravenous access. More research in the 
study of medications addressing the pathophysiology of sickle cell crisis pain is needed, with 
access to identifying repeat failures of opioid and NSAID treatment in this patient population. 
Healthcare providers need to address the multidimensional elements in developing evidenced-
based, individualized strategies in the treatment of pediatric sickle cell crisis pain in the hospital 
setting. 
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Figure 7. Flowchart of multidimensional components in the treatment of pediatric sickle cell 
crisis pain. Adapted from Ballas, 2014; Hagedorn and Monico, 2016; Jaja et al., 2014; Nottage et 
all. 2016; Raphael et al., 2013; Yee et al., 2013; 
Implications for Research 
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 The major impediment in the development of generalizable evidence-based safe and 
effective pharmacological intervention of pediatric sickle cell crisis pain is study designs that 
lack adequate sample size. The inability to obtain larger sample sizes and multicenter trials leads 
to inferences and inappropriate treatment of children with sickle cell crisis pain. Obtaining 
consent and assent during the time of patient distress has been inadequate, leading to minimal 
participation. The development of study designs in which participation is discussed and 
consent/assent obtained, with a method to identify participants upon arrival at the hospital 
setting, has the potential of increasing participation when patient distress from sickle cell crisis 
pain is not a factor in the decision. 
Dissemination 
 
The purpose of this integrative review of the pharmacological pain management of 
pediatric sickle cell crisis pain was to provide a systematic review of separate evidence-based 
findings in a format to define the state of knowledge. The public presentation of the summation 
of accumulated knowledge concerning the pharmacological pain management of pediatric sickle 
cell crisis pain will utilize the internal organization pain service and poster presentation at the 
annual hospital nursing research symposium for 2019. Development of a manuscript for 
publication in a professional nursing journal is in progress.  
   
DNP ESSENTIALS 
 
Essential I 
 
The DNP scholarly project assisted in enhancing nursing knowledge in understanding the 
impact of under-treatment of pediatric sickle cell pain crisis and the processes needed to affect 
positive changes in the pain experience of such patients. The utilization of Essential I 
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incorporated scientific knowledge and expert opinions from other sciences in collaboration with 
nursing midrange theory of symptom management in decreasing the intensity, frequency, and 
episodes of sickle cell pain crisis (Smith & Lieher, 2014). The integrative review, a form of 
systematic review, is “the strongest level of evidence to guide intervention for clinical practice” 
(Fineout-Overholt et al., 2005, p. 336) allowing nursing at the practice level to incorporate 
evidence-based practice in the care of children with sickle cell pain crisis. The project 
encourages discussion among stakeholders in collaboration across all entries into the healthcare 
system in the effective management of sickle cell pain crisis in children. The DNP is positioned 
to mentor nurses in the evidence-based practice process facilitating shorter intervals between 
research, policy, and patient care. 
Essential VIII 
 
This prepares the DNP project leader to facilitate participation in evidence-based 
management of pediatric sickle cell crisis pain among patients, families, nursing, and other 
healthcare providers sustaining therapeutic relationships to facilitate improved patient outcomes 
and satisfaction. Essential VIII focus on equipping DNP graduates in the mastery of 
comprehensive, systematic health assessments designing, implementing, and evaluating 
interventions based on nursing science and other sciences (American Association of Colleges of 
Nursing, 2006). Children experiencing sickle cell crisis pain enter the healthcare system at a 
variety of entry points of care and hours of operation, necessitating the need of effective 
communication within the complex healthcare system. The project will give advance practice 
nurses and nurses practicing in rural areas the knowledge needed to manage children 
experiencing sickle cell pain crisis, using evidence-based guidelines to develop specific 
treatment regimens according to resources, improving outcomes and providing quality patient 
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care. The rigor of the integrative five-step review process by Harris Cooper (1982) assists in the 
translation of research into practice and provides the framework to redesign effective and 
realistic pain management strategies in the care of children with sickle cell crisis pain. 
Continuing to analyze the research for the prevention of the pain cycle in this patient population 
is crucial in reducing the risk of morbidity, mortality, and premature death in which the skills of 
the DNP as a leader and mentor are much needed in advancing nursing practice and the nursing 
profession. 
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Table 1 
Levels of Evidence for Project Literature Reference 
Evidence category  Numeric level Number of articles for 
project 
Systematic review & meta-
analysis of randomized 
controlled guidelines 
 
1 2 
One or more randomized 
controlled trials 
2 7 
Controlled trial (no 
randomization) 
3 1 
Case-control or cohort study 4 0 
Systematic review of 
descriptive & qualitative 
studies 
5 3 
Single descriptive or 
qualitative study 
6 6 
Expert opinion 7 1 
 
 
Table 2 
 
Inclusion and Exclusion Criteria 
 
 
Inclusion criteria Exclusion criteria 
Dates 2012 to 2017 Dates prior to 2012 
Children ages 0 years to 21 years Children older than 21 years 
Full text articles Abstract only articles 
Studies performed in the U.S.; Peer-reviewed 
articles at all levels per Melnyk Levels of 
Evidence (2015) 
Studies outside of the U.S. 
English language  Non-English languages  
Pharmacological pain management therapies Non-pharmacological, complementary, and 
alternative therapies 
 
 
PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN 46 
 
Table 3 
 
Results Matrix for Pain and Pediatric Sickle Cell Disease 
 
Focus of Article, 
Author, and Year 
Critique: Level of 
Evidence and Source 
Pediatric Sickle Cell 
Pain/Background 
Conclusions Practice Implications and 
Recommendations 
Principles of vaso-
occlusive crisis 
management and 
pharmacogenomics of 
opioids (Ballas, 2014) 
Level 5: Systematic 
review of descriptive 
and qualitative studies 
 Healthcare 
providers’ 
knowledge of 
sickle cell pain 
management 
was suboptimal 
in the 1950’s-
1970’s. 
 Many people 
with sickle cell 
disease died 
during 
childhood and 
young 
adulthood. 
 Recent life 
expectancy 
ranges from 
50-70 years. 
 Chronic pain is 
more common 
and severe. 
 Dorsal horn is 
main pathway 
to central 
 Opioids are the 
most commonly 
used analgesic in 
the management of 
sickle cell pain. 
 Gap between new 
advances in 
pathophysiology of 
pain, 
pharmacogenomics 
of opioids, and the 
clinical 
management of 
sickle cell pain 
 The 
pathophysiologic 
mechanism of 
sickle cell vaso 
occlusive crisis 
varies depending 
on the clinical 
presentation. 
 Specific analgesics 
should be aligned 
with the specific 
 Understanding of 
the 
pathophysiologic 
mechanism of pain 
and 
pharmacogenomics 
of opioids has 
improved 
significantly. 
 Clinical 
management of 
sickle cell pain 
does not reflect 
new knowledge. 
Recommendations 
 Determine 
analgesics in 
alignment with 
specific 
pathophysiologic 
mechanism and 
pharmacogenomics 
of opioids. 
 Clinical trials to 
determine clinical 
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nervous system 
pain relief 
efforts by the 
endogenous 
endorphins. 
 Two Na+ 
channels 
receptors (a-
Amino-3-
hydroxy-
5methyl-4-
isoxazolepropi
onic acid 
(AMPA) and 
N-methyl-
Daspartic acid 
(NMDA) 
which 
determine the 
type, severity, 
and duration of 
vaso-occlusive 
pain crisis 
 The AMPA 
and NMDA 
allow for 
effective pain 
relief with non-
opioids and 
opioids unless 
pathophysiologic 
mechanism and 
pharmacogenomics 
of opioids. 
efficacy of opioids 
and CYP genotypes 
in patients with 
sickle cell pain. 
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aberrant. 
metabolism 
exist 
 With the many 
advances in 
treating sickle 
cell disease 
minimal 
advances in 
management 
sickle cell pain 
are noted. 
The focus of this 
study is to determine 
the frequency of 
CYP2C9 alleles and 
genotypes in children 
with sickle cell 
disease in the U.S. 
and African American 
populations (Jaja et 
al., 2014). 
Level 2: Randomized 
controlled trial 
 GI 
complications, 
renal 
impairment, 
fluid retention, 
asthma 
exacerbation 
are some of the 
adverse effects 
associated with 
impaired 
NSAID 
metabolism. 
 
 Study showed 30% 
of subjects with at 
least one allele 
associated with 
reduced function in 
metabolizing 
NSAIDS. 
 Sickle cell disease 
patients have a 
slightly higher 
frequency of the 
CYP2D6 gene 
deletions compared 
to healthy African 
Americans related 
to opioid 
conversion. 
 NSAIDs are the 
 Inform genomic-
based drug 
prescribing practice 
 
 The CYP2C9 
variants play an 
important role in 
the analgesic effect 
and toxicity of 
NSAIDS. 
Recommendations 
 Preemptive 
genotyping would 
provide explanation 
for those 
individuals with 
unsatisfactory drug 
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backbone of pain 
management of 
children with sickle 
cell disease. 
response or side 
effects profiles 
enabling clinicians 
to make 
distinctions 
between a 
compliance 
problem and a 
metabolic defect. 
 Future studies to 
determine the 
CYP2C9 profiles 
of sickle cell 
disease patients 
that could 
potentially enable 
clinicians to 
identify patients 
with impaired 
CYP2C9 metabolic 
capacity and tailor 
NSAIDs dosing 
accordingly to 
achieve optimal 
analgesic response. 
The focus of this 
study is to determine 
the frequency of 
CYP2D6 alleles and 
genotypes in children 
Level 2: Randomized 
controlled trial 
 For codeine 
and 
hydrocodone 
CYP2D6 is the 
first step in the 
 Morphine clearance 
is significantly 
higher in patients 
with sickle cell 
disease compared 
 Sickle cell disease 
patients may 
require higher and 
more frequent 
opioid doses to 
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with sickle cell 
disease in the U.S. 
and African American 
populations (Yee et. 
al, 2013). 
pathway of 
opioid 
analgesic 
effect, 
converting the 
prodrug to 
morphine or 
hydromorphon
e respectively. 
 CYP2D6 
testing should 
be considered 
in patients with 
repeated failed 
outpatient pain 
management. 
 Opioid 
medications 
such as 
morphine or 
hydromorphon
e that do not 
require 
enzymatic 
activation may 
produce better 
analgesia in 
this patient 
population. 
to non-sickle cell 
disease individuals. 
 Limitation includes 
the inability to 
identify less 
common CYP2D6 
alleles. 
maintain adequate 
analgesia. 
 Genetic variations 
in the CYP2D6 
gene may 
contribute to poor 
responses to 
common pain 
medications for 
outpatient sickle 
cell pain 
management.  
 Personalized 
medicine along 
with genetic testing 
will assist 
clinicians to predict 
response to 
medications and 
tailor treatments-
based on genetic 
polymorphisms. 
Recommendations 
 Larger studies of 
CYP2D6 
genotypes need to 
be accomplished. 
 Further study of the 
extent of CYP2D6 
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contribution to 
failed outpatient 
pain management 
among sickle cell 
disease in children 
Determine whether 
administrative data 
have the capacity to 
fully assess health 
care utilization among 
children with sickle 
cell disease (Raphael, 
2013). 
Level 6: Single 
descriptive study 
 The average 
medical fee for 
a child with 
sickle cell 
disease during 
childhood ages 
1-18 years is 
approximately 
1,354,000 U.S. 
dollars. 
 Administrative 
claims data 
provided key 
insights into the 
scope of health 
services use 
including how and 
where services are 
being used and 
highlights the 
limitations of sole 
reliance on 
Medicaid record 
reviews. 
 Despite progress in 
the evaluation and 
management of 
sickle cell disease 
care of affected 
children, this 
medical illness 
continues to be a 
high-cost and 
resource-intensive 
disease. 
Recommendation 
 Development of 
guidelines to 
decrease pain 
frequency and 
intensity 
 Enhance provider 
knowledge of 
effective pain 
treatment 
modalities 
 High quality 
research 
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development to 
provide evidence-
based treatment 
regimens  
 Development of 
intercollaborative 
teams with 
appropriate 
stakeholders  
 
 
Table 4 
 
Result Matrix Pain Management and Sickle Cell Pain Guidelines and Reviews 
 
Focus of Article, 
Author, and Year 
Critique: Level of 
Evidence and Source 
Sickle Cell Pain 
Guidelines and 
Reviews/Background 
Conclusions Practice Implications 
and Recommendations 
The focus of this 
article is to provide a 
digital resource of the 
treatment 
recommendations 
extracted from the full 
report in the evidence-
based treatment of 
sickle cell disease 
(National Heart, Lung, 
Blood Institute, 2014). 
Level 7: Expert panel  
 
 Of the 17 
recommendatio
ns, 9 
recommendatio
ns are related to 
the 
pharmacologica
l treatment of 
vaso-occlusive 
pain, and 10 
recommendatio
ns are related to 
 The range of 
panel expert 
consensus 
included 
initiation of 
analgesic within 
30 minutes of 
triage or 60 
minutes of 
registration, 
basing analgesic 
use on pain 
 For severe pain, 
consider 
escalation of the 
opioid dose by 
25% until pain 
control. 
 To prevent over 
sedation, consider 
the need of long-
acting opioids 
with continuous 
PCA opioid use. 
PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN 53 
 
 
 
 
assessment, 
hydration, 
blood 
transfusion, 
oxygen therapy, 
and non-
pharmacologica
l treatment 
 Of the 9 
pharmacologica
l 
recommendatio
ns, a majority 
of the evidence 
was based on 
consensus 
consisting of 
the American 
pain society 
with evidenced 
reviewed by the 
methodology 
team of panel 
of experts. 
 Of the 9 
recommendatio
ns only 1 had 
high-quality 
evidence and 
strong 
assessment and 
patient past use 
of analgesic with 
relief of pain 
symptom. 
 
Recommendations 
 Use subcutaneous 
route of 
medication 
administration 
when intravenous 
access is difficult. 
 For severe pain, 
reassess every 15-
30 minutes until 
pain is under 
control per patient 
report. 
 When using PCA 
on demand 
consider long-
acting opioids 
 Do not use 
meperidine unless 
it is the only 
effective opioid 
for the individual. 
 Gradual titration 
of parenteral 
opioids as sickle 
cell disease crisis 
pain resolves. 
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recommendatio
n associated 
with rapid 
initiation of 
parenteral 
opioids for the 
treatment of 
sickle cell 
disease crisis 
pain. 
 2 low quality 
evidences, 
moderate 
recommendatio
ns associated 
with treatment 
of NSAIDS for 
mild to 
moderate pain 
in the absence 
of 
contraindication
s and around 
the clock 
continuous 
infusion of 
opioids 
utilizing PCA 
versus prn 
administration 
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 6 
recommendatio
ns were of 
consensus and 
panel expertise. 
The focus of this 
guideline is to provide 
evidence-based 
recommendations for 
the treatment of pain 
including opioids, non-
opioids, and adjuvant 
medications to improve 
the management of 
pain in children 
experiencing pain 
related to medical 
diseases (World Health 
Organization, 2012). 
Level 7: Expert panel 
 
 Low quality of 
evidence, 
strong 
recommendatio
n for strong 
opioids as an 
essential 
medication in 
the treatment of 
sickle cell 
disease pain 
 There is no 
other class of 
medication than 
strong opioids 
that is effective 
in the treatment 
of moderate to 
severe sickle 
cell disease 
pain. 
 Acute pain is a 
sudden onset 
felt 
immediately 
 Development of 
a 2-step 
approach 
incorporating 
dosing at regular 
intervals, using 
appropriate route 
of medication 
administration, 
and adapting 
treatment to 
individual child 
 2 step 
approaches are a 
revision of the 3-
step analgesic 
ladder of 1986, 
which 
recommended 
use of codeine as 
a weak opioid 
while the 2-step 
approach 
considers low 
doses of strong 
 The effectiveness 
of codeine is in 
question related to 
the percentage of 
poor metabolizers 
resulting in the 
effectiveness of 
this medication. 
 There is no 
available evidence 
of the comparative 
effectiveness and 
safety of 
Tramadol in 
children, no 
license for 
pediatric use in 
several countries 
and more research 
needed. 
 Steroids 
(corticosteroids) 
and 
bisphosphonates 
(bone pain) are 
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following 
injury, severe in 
intensity, arises 
because of 
tissue injury 
stimulating 
nociceptors and 
generally 
disappears 
when injury 
heals. 
 Sickle cell 
disease pain is 
generally 
nociceptive 
superficial and 
deep somatic 
visceral pain 
arising from 
internal organs, 
bones, joints, 
muscles, 
connective 
tissue, nose, 
urethra, anus, 
skin, and nose. 
 Sickle cell 
disease arms, 
legs, abdomen, 
chest, and back 
opioids for the 
treatment of 
moderate pain  
 2-step strategy 
strong 
recommendation 
with very low 
quality of 
evidence 
not recommended 
as adjuvants in the 
treatment of sickle 
cell disease pain 
in children. 
 At the time of this 
guideline not 
possible to make 
recommendations 
because of limited 
studies on the use 
of gabapentin and 
sub-anesthetic 
dose of ketamine 
 Fear and lack of 
knowledge are a 
barrier to the 
relief of pain 
using opioids in 
children. 
 The World Health 
Organization 
included 
morphine as an 
essential 
medication in the 
treatment of pain 
in children. 
 No evidence 
among children or 
PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN 57 
 
 
 
 
pain generally 
last 4-5 days. 
adults to 
recommend 
opioid rotation to 
prevent side 
effects of dose 
escalation. 
 
Recommendations 
 Utilize 2-step 
strategy in the 
treatment of sickle 
cell disease pain 
in children. 
 First step is the 
treatment of mild 
pain with 
paracetamol and 
ibuprofen, a 
strong 
recommendation 
with low quality 
evidence. 
 Second step is the 
treatment of 
moderate to 
severe pain with 
morphine as the 
drug of choice. 
 Medication should 
be administered at 
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regular intervals 
using the 
appropriate route 
of administration, 
adapting the 
treatment to the 
individual child. 
 Adjuvant 
medicines may be 
co-administered 
with analgesic to 
enhance pain 
relief. 
 
The focus of this 
article is to provide a 
definitive reference for 
the use of ketamine 
infusion for pain 
management among 
persons with sickle cell 
pain (Hagedorn & 
Monico, 2016). 
Level 5:  Systematic 
review of descriptive and 
qualitative studies 
 Sickle cell pain 
effectively 
managed in the 
emergency 
department and 
hospital using 3 
major classes of 
medications: 
opioids, non-
opioids, and 
adjuvants 
 Most common 
opioids: 
morphine, 
hydromorphone
, and fentanyl. 
 Ketamine 
infusion may 
provide adequate 
pain relief for 
those who have 
failed the typical 
pain 
management 
regimen. 
 Ketamine 
infusions used 
with opioids 
reduce opioid 
usage. 
 Adverse effects 
 Ketamine may be 
a useful adjuvant 
with opioid when 
high doses result 
in no analgesic 
effect. 
 Ketamine 
infusions are to be 
performed in the 
hospital setting 
where adverse 
reactions can be 
managed. 
Recommendations 
 No specific 
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 Non-opioid 
medications 
include 
nonsteroidal, 
anti-
inflammatories, 
acetaminophen, 
and tramadol. 
 Adjuvant 
medications 
include 
antidepressants, 
benzodiazepine
s, 
antihistamines, 
and 
anticonvulsants. 
 Non-
pharmacologica
l therapies 
include 
psychological 
evaluation; 
occupational, 
behavioral, and 
cognitive 
therapy; 
acupuncture; 
exercise; 
massage; and 
were 
hypertension, 
unresponsivenes
s, nystagmus, 
and dysphoria. 
recommendations 
can be made until 
further studies are 
performed using 
Ketamine 
infusions among 
pediatric patients 
with sickle cell 
pain. 
 Ketamine 
infusions may be 
useful in treating 
pediatric sickle 
cell pain 
refractory to other 
standard 
treatment. 
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aqua therapy. 
The focus of this 
article is to determine 
prospectively whether 
a clinical pathway 
improves the acute 
management of sickle 
cell disease vaso-
occlusive pain in the 
pediatric emergency 
department (Ender, 
2014). 
Level 3: Control trial, no 
randomization 
 Inadequate 
treatment of 
pain is 
associated with 
fatal 
complications 
such as acute 
chest syndrome. 
 Patients with 
highest pain 
scores have 
historically had 
increased risk 
of early death 
compared to 
those with the 
lowest pain 
scores. 
 Clinical 
pathways for 
other pediatric 
diseases than 
sickle cell 
disease have 
shown to 
promote more 
rapid 
stabilization, 
decrease 
 Clinical 
pathways can 
improve 
important 
aspects of pain 
management 
such as time to 
first analgesic, 
time to first 
opioid, increased 
use of ketorolac. 
There was no 
significant 
change in pain 
scores. 
 
 Clinical pathways 
in children with 
sickle cell disease 
will need to 
address 
multifactorial 
causes of pain and 
treatment 
strategies. 
Recommendations 
 Further studies on 
developing 
clinical pathways 
with 
multidisciplinary 
teams including 
emergency 
department 
physicians, 
hematology 
physicians, 
pharmacists, 
nursing, and 
patient/families. 
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hospital 
admission rates, 
and reduce the 
use of 
inappropriate 
therapies. 
Individualized pain 
management plans 
developed because of 
successful 
implementation of a 
standard protocol 
jointly by the 
emergency department 
physician and primary 
hematologist improve 
patient satisfaction 
with pain management 
and reduce hospital 
admissions as well as 
readmission rates 
(Krishnamurti, 2014). 
Level 6: Single 
descriptive study 
 Algorithm 
emphasized 
early initiation 
of treatment 
with 
intravenous 
morphine of 
hydromorphone 
with the goal of 
obtaining 
significant pain 
relief within 1-2 
hours of arrival 
at the 
emergency 
department. 
 Study 
demonstrated 
that detailed 
individualized 
pain 
management 
plans 
implemented in 
collaboration 
between the 
patient, 
hematologist, 
and emergency 
department staff 
can improve 
management of 
sickle cell 
associated vaso-
occlusive crisis 
in the emergency 
department. 
 Project compared 
admission and 
readmission rates 
within a week and 
average length of 
hospital stay. 
 Reduction in 
length of hospital 
time served as an 
indicator of 
effective pain 
management in 
the emergency 
department as 
well as during 
hospitalizations. 
Recommendations 
 Each plan 
included a list of 
current home 
medications, other 
medications, 
analgesic dosage, 
and frequency of 
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administration for 
emergency 
department care 
and inpatient pain 
medication 
regimen. 
 Sickle cell nurse 
coordinator 
visited each 
patient during 
weekday daytime 
hours and 
supported 
emergency 
department staff. 
 After hours 
emergency 
department staff 
interacted with 
hematology/oncol
ogy fellow on call. 
Identify factors 
associated with delays 
in treatment of sickle 
cell disease pain crisis 
in the emergency 
department with goal 
of discerning whether 
earlier pain 
management is 
Level 6: Single 
descriptive study 
 The number of 
people with 
sickle cell 
disease is 
estimated to be 
72,000 to 
98,000 when 
corrected for 
 Patient 
experienced 
significant 
delays to initial 
analgesic 
medications. 
 A standardized 
approach to pain 
management may 
improve 
emergency 
department 
management of 
sickle cell disease 
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correlated with better 
clinical outcomes (Lin, 
2016). 
early mortality. 
 Sickle cell 
disease patients 
have highest 
pain scores of 
all emergency 
department 
diagnosis, with 
a mean score of 
8.7 of 10. 
 Leading causes 
of mortality 
include 
bacterial 
infections from 
encapsulated 
organisms at 
38%, cerebral 
vascular 
accidents at 
12.3%, and 
acute pain 
episodes and 
acute chest 
syndrome at 
11%. 
 Opioids are 
most common 
initial pain 
medication 
pain crisis. 
 Improved pain 
management may 
help prevent 
admissions from 
sickle cell pain 
and may decrease 
acute chest 
syndrome and 
mortality from 
sickle cell disease. 
Recommendations 
 Management of 
severe pain 
primarily with 
opioids with 
potential addition 
from classes of 
analgesics and 
adjuvants 
 Other classes of 
analgesics include 
NSAIDS, topical 
agents, 
corticosteroids. 
 Adjuvants 
including 
antihistamines, 
benzodiazepines, 
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prescribed and 
administered. 
 Second most 
common 
medications 
prescribed and 
administered 
are NSAIDS, 
most common 
ketorolac as 
initial therapy 
with 60% 
receiving 
opioids. 
 9% of pediatric 
emergency 
department 
physicians 
report 
following an 
institutional 
protocol when 
treating pain 
due to sickle 
cell disease. 
 2 factors 
causing delays 
include time 
required in 
reviewing 
antidepressants, 
anticonvulsants, 
and 
phenothiazines 
may enhance the 
analgesic potential 
and ameliorate 
potential adverse 
effects. 
 Future use of 
electronic 
ordering system 
alerting provider 
when a patient 
had not received 
first medication 
dose 
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patient chart 
and deciding 
optimal pain 
management 
regimens. 
 
 
Table 5 
 
Results Matrix for Pain Management and Sickle Cell Pain Research Trials 
 
Focus of Article, 
Author, and Year 
Critique: Level 
of Evidence and 
Source 
Research 
Trials/Background 
Conclusions Practice Implications 
and Recommendations 
Arginine as a safe 
and inexpensive, 
and narcotic-sparing 
intervention in the 
treatment of sickle 
cell pain in children 
(Morris, et, al., 
2013) 
Level 2: 
Randomized 
controlled trial 
 Arginine is an 
obligate substrate for 
nitrous oxide 
production, and acute 
deficiency is 
associated with pain. 
 Single center, 
prospective, 
randomized, double-
blinded, placebo-
controlled trial 
 38 patients ages 3-19 
years with an average 
age of 13.9 +/- 4 years 
 No significant 
difference in length of 
hospital stay between 
arginine and placebo 
group 
 54% reduction in 
opioid use in the 
arginine group during 
hospitalization 
 Pain scores at 
discharge in the 
arginine group were 
significantly lower 
than the placebo 
group. 
 No safety 
concerns have 
emerged with 
arginine use. 
 Patients prefer IV 
instead of oral 
administration of 
arginine. 
 Reduction in 
opioid use by 54% 
 Beneficial adjunct 
to standard 
therapy 
Recommendations 
 Multicenter trial 
with larger cohort  
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 Multicenter trial 
with cross-over 
during 
hospitalization 
 
Evaluate methadone 
pharmacokinetics in 
children and adults 
with sickle cell 
disease with 
secondary aim to 
assess pain relief 
and opioid 
consumption (Horst, 
2015). 
Level 2: 
Randomized 
controlled trial 
 Morphine is the 
opioid most 
commonly used to 
treat pain associated 
with sickle cell 
disease and is the only 
opioid with 
previously defined 
intravenous 
pharmacokinetics in 
children with sickle 
cell disease. 
 Methadone may have 
several therapeutic 
advantages compared 
with morphine, 
including a more 
rapid onset of effect, 
longer elimination 
half-life and duration 
of effect, greater 
bioavailability, and 
absence of active 
metabolites. 
 Methadone produced 
more pain relief than 
standard care in 
children with sickle 
cell disease. 
 Higher plasma 
concentrations of S-
methadone and faster 
systemic elimination 
of S-methadone 
comparable with 
children receiving IV 
methadone during 
major surgery 
 Sickle cell disease 
does not alter the 
pharmacokinetics of 
methadone in 
children. 
 Pain relief scores at 
baseline did not 
differ, but pain relief 
was significantly 
greater at 12, 24, and 
 Morphine may not 
be optimal choice 
as it has an 
increased 
clearance and 
shorter half-life in 
patients with 
sickle cell disease, 
resulting in 
increasing doses 
to achieve 
analgesia. 
 Morphine used in 
sickle cell disease 
has also been 
associated with an 
increased risk of 
acute chest 
syndrome 
compared with 
nalbuphine and a 
slower onset of 
pain relief 
compared to other 
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48 hours in children 
receiving methadone. 
opioids. 
 Previous 
pharmacokinetics 
of methadone 
parameters can be 
used to guide 
dosing in children 
with sickle cell 
disease. 
 Methadone, a 
NMDA receptor 
agonist, may 
reduce the 
positive feedback 
loop associated 
with hyperalgesia. 
Recommendations 
 Further 
evaluations of the 
effectiveness and 
safety of higher 
initial IV dose of 
methadone in 
children with 
sickle disease pain 
Effects of 
subanesthetic 
Ketamine on pain 
intensity and opioid 
Level 6: Single 
descriptive study 
 Chart review of 
patients receiving 
Ketamine infusions 
 Included pain 
 Ketamine infusions 
safe in the hospital 
setting 
 Best results in cancer 
 Use in the in-
patient treatment 
of cancer-related 
pain 
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use (Sheely et.al, 
2017) 
diagnosis of vaso 
occlusive crisis and 
sickle cell disease 
 230 patients and 360 
separate hospital 
admissions infusions 
were eligible 
 Greater median 
reductions in opioid 
intake with sickle cell 
patients and patients 
with malignancy-
associated pain 
pain 
 Study does not 
examine effect on 
chronic postsurgical 
pain. 
 No control group for 
this study and caution 
needed in 
generalizing results 
 No significant 
psychotropic 
effects and 
hemodynamic 
side effects 
 Possible 
hypertension 
during Ketamine 
infusion may 
require vasoactive 
drugs. 
Recommendations 
 More clinical 
trials with control 
group 
Gabapentin in the 
treatment of vaso-
occlusive 
neuropathic pain 
(Nottage, 2016) 
Level 2: 
Randomized 
controlled trial 
 Research concentrated 
on prevention of vaso-
occlusive crisis with 
use of hemoglobin F-
inducing agents, 
principally 
hydroxyurea, little 
effort toward 
investigating 
management of acute 
pain crisis in children 
 Allodynia and 
hyperalgesia are 
common symptoms of 
 This trial is open and 
started 2 years prior to 
January 2016 and will 
continue for 2 more 
years. At the end it 
will answer the 
question regarding 
gabapentin as an 
effective home use in 
conjunction with oral 
opioids and non-
opioids at the time of 
pain onset, with the 
goal of reducing the 
 
 Recognition that 
pain is 
nociceptive and 
neuropathic 
 Concurrent use of 
morphine and 
gabapentin 
provide better 
analgesic at low 
doses than single-
agent therapy. 
 A single high dose 
of gabapentin 
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sickle cell pain and 
defining 
characteristics of 
neuropathic pain. 
 Opioids act on µ 
receptors, non-
steroidal drugs inhibit 
cyclooxygenase, and 
gabapentin-related 
medications affect the 
ά2δ subunit of the 
voltage dependent 
calcium channel. 
 Synergy of morphine 
and gabapentin likely 
result of actions on 
peripheral and central 
nervous systems 
 Sickle cell pain crisis 
is the leading cause of 
hospitalizations and 
drivers of healthcare 
expenditure in the 
sickle cell population. 
 Pain is addressed 
inadequately in most 
clinical settings, and 
current treatment 
strategies are 
unsatisfactory. 
need for acute visits 
to the emergency 
department and 
hospitalizations for 
vaso-occlusive pain 
crisis. 
decreases time 
delays to first 
request for 
analgesia, 
decrease pain 
intensity, and  
decrease opioid 
consumption 
Recommendations 
 Limiting factor 
for completing 
research trials 
among this patient 
population related 
to patient 
presenting in 
distress hindering 
their ability to 
give 
consent/assent. 
PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN 70 
 
 
 
 
 Drugs targeting 
neuropathic pain have 
not been studied 
prospectively. 
 
To determine if 
children with vaso-
occlusive pain crisis 
who receive initial 
treatment with 
intranasal fentanyl 
compared to 
placebo achieve a 
greater decrease in 
pain score after 20 
minutes (Fein, 
2016) 
Level 2: 
Randomized 
controlled trial 
 Pain accounts for 
approximately 70% of 
emergency 
department visits for 
children with sickle 
cell disease. 
 Delay in obtaining 
intravenous access in 
children with sickle 
cell disease is related 
to scarring of veins 
from frequent blood 
draws and prior 
episodes of 
intravenous access. 
 20 minutes chosen 
because it 
corresponds to the 
time after peak serum 
concentration and the 
known onset of 
therapeutic effect of 
intranasal fentanyl 
and within the 
National Heart Lung 
 Greater decrease in 
pain scores at 20 
minutes after 
administration of 
intranasal fentanyl 
 Possible that 
transmucosal 
absorption of 
intranasal fentanyl 
is different in a 
child with vaso-
occlusive pain 
crisis related to 
microvascular 
congestion in the 
nasal capillary 
bed, resulting in 
either less drug 
being absorbed or 
needing greater 
time until drug 
absorption, thus 
prolonging the 
time of 
therapeutic effect 
 Intranasal fentanyl 
may serve as a 
noninvasive way 
to bridge the gap 
until intravenous 
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Blood institute 
recommended 
timeframe for 
reassessment of pain 
after analgesic 
administration 
 Intranasal medications 
are easily 
administered; rapid 
onset of action avoids 
the gastrointestinal 
tract and hepatic first 
pass metabolism and 
by-passes the brain-
blood barrier 
specifically targeting 
the central nervous 
system. 
access can be 
obtained and 
further parenteral 
analgesics can be 
administered. 
Recommendations 
 To not force 
decision making 
while under the 
emotional duress 
of a vaso-
occlusive pain 
crisis, obtain 
consent/assent by 
pre-enrolling 
during outpatient 
hematology visit 
separate from 
pediatric 
emergency 
department visit. 
 
Hospital case report 
of 3 patients who 
during vaso-
occlusive pain crisis 
had severe pain 
unresponsive to 
opioids and 
ketamine and were 
Level 6: Single 
descriptive study 
 Most approaches to 
treat sickle cell 
disease pain have 
poor levels of 
evidence, being based 
on observational 
studies and expert 
 Dexmedetomidine in 
combination with 
opioid and ketamine 
is well tolerated and 
temporarily associated 
with reduction in 
opioid requirements 
 Some sickle cell 
disease patients 
develop 
pulmonary 
hypertension, 
which is a known 
independent risk 
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treated with 
dexmedetomidine. 
(Sheely, 2015) 
opinions rather than 
on clinical trials. 
 Providers mostly treat 
symptoms because 
mechanism-based 
strategies for sickle 
cell disease associated 
pain are sorely 
lacking. 
 Dexmedetomidine 
without respiratory 
depressant effect used 
as sedative and/or 
analgesic during 
perioperative period 
and intensive care 
units 
and improved pain 
scores. 
factor for 
mortality. 
 Theoretical 
concern for 
vasoconstrictive 
effect of 
pulmonary 
vasculature 
Recommendations 
 Trained registered 
nurses to 
administer 
subanesthetic 
doses of ketamine 
providing 
monitoring of 
heart rate, oxygen, 
and blood 
pressure with 
starting ketamine 
dose of 0.1 
mg/kg/hr. per 
attending 
physician 
discretion. 
Low dose ketamine 
as an adjuvant to 
opioids as a 
therapeutic option 
Level 5: 
Systematic review 
of descriptive and 
qualitative studies 
 Ketamine is a non-
barbiturate 
phencyclidine that 
provides analgesia in 
 Emerging data 
suggest role of N-
methyl-D-aspartate 
(NMDA) receptor in 
 Ketamine has an 
inotropic action 
and induces 
vasoconstriction 
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to manage 
refractory sickle cell 
disease related pain 
(Neri, 2013) 
the brain and spinal 
cord. 
 Modulate opioid 
tolerance and opioid-
induced hyperalgesia 
 Low-dose ketamine 
decreases heart rate 
and blood pressure. 
 Low dose ketamine 
used in the 
management of acute 
post-operative pain in 
non-sickle cell disease 
patients 
 Few studies evaluated 
ketamine in sickle cell 
disease patients. 
 Most studies included 
small case review 
numbers with 
improved pain control 
and decreased 
morphine use after 
addition of ketamine. 
opioid tolerance and 
opioid induced 
hyperalgesia. 
by inhibiting 
nitrous oxide 
production, 
resulting in 
increased heart 
rate and blood 
pressure. 
 Ketamine 
increases 
myocardial 
oxygen demand. 
Recommendations 
 Studies with 
larger numbers 
evaluating 
ketamine as 
adjuvant to pain 
management of 
sickle cell disease 
pain in children 
Hypothesized that 
the addition of 
intravenous 
magnesium to 
standard therapy 
would shorten 
Level 2: 
Randomized 
controlled trial 
 Several multicenter 
trials in the setting of 
sickle cell pain crisis 
have been closed 
because of inadequate 
enrollment, making 
 Intravenous 
magnesium did not 
shorten length of stay, 
reduce opioid use, or 
improve quality of life 
in children 
 Oral magnesium 
used previously to 
prevent pain crisis 
with some 
preliminary 
success, but 
PAIN MANAGEMENT IN PEDIATRIC SICKLE CELL PAIN 74 
 
 
 
 
hospital stay, 
decrease opioid use, 
improve health-
related quality of 
life for pediatric 
patient hospitalized 
with sickle cell 
disease pain crisis 
(Brousseau, 2015) 
advancements in the 
field difficult. 
 Magnesium is a 
known vasodilator 
with anti-
inflammatory effects 
and has the potential 
to alter the 
pathophysiology of 
pain crisis. 
 2 previous 
intravenous 
magnesium studies 
single institution 
trials. One showed 
shortened length of 
stay from 5 to 3 days 
and a Canadian study 
with no decrease in 
length of stay.  
 Oral magnesium 
studied in the 
prevention of painful 
crisis not the 
treatment of acute 
painful crisis 
 Main discharge 
criterion was the 
ability of the patient 
to control pain with 
hospitalized for sickle 
cell disease pain 
crisis. 
medication not 
well tolerated 
Recommendations 
 Research trials 
using oral 
magnesium and 
development of a 
more tolerated 
oral formulation 
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oral opioids. 
Describe the 
methods of the 
intravenous 
magnesium in sickle 
cell vaso-occlusive 
crisis in the 
Magnesium for 
Children in Crisis 
(MAGiC) study and 
discuss methods 
used to overcome 
barriers (Badaki-
Makun, 2014). 
Level 1: 
Systematic review 
of randomized 
controlled 
guidelines 
 Sickle cell disease is 
one of the most 
common inherited 
hemoglobinopathies 
in the world. 
 Most of morbidity of 
sickle cell disease is 
due to recurrent vaso-
occlusive pain crisis 
resulting in 
hospitalizations and 
effects on quality of 
life. 
 Current management 
based primarily on 
expert opinion with 
evidenced-based acute 
management derived 
from small and often 
inadequate powered 
sickle cell disease 
specific studies or 
studies of non-sickle 
cell disease pain 
 Staff availability and 
delay in initiation of 
study medication was 
resolved by utilizing 
the Pediatric 
Emergency Care 
Applied Research 
Network (PECARN) 
which provided in-
person emergency 
department coverage 
and on-call coverage. 
 Protocol related 
factors resolved with 
participation of other 
departments such as 
pain management, 
anesthesia, pharmacy, 
nursing 
 Patient related factors 
resolved with 
consenting 
patient/families 
during routine care in 
the hematology clinic 
 In the U.S. 18,000 
hospitalizations 
and 75,000 
hospital days are 
experienced 
annually of 
children with 
sickle cell disease. 
 28% of children 
with sickle cell 
disease admitted 
for vaso-occlusive 
pain crisis are 
readmitted within 
30 days for 
another crisis. 
Recommendations 
  
Adequate and 
timely pain 
management 
improves quality of 
Level 6: Single 
descriptive or 
qualitative study 
 Comprehensive 
emergency 
department guidelines 
for assessment and 
 Patients who receive 
combination treatment 
were less likely to be 
admitted from the 
  
 
Recommendations 
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life, and rapid 
evaluation of pain is 
critical to ensure 
quick pain relief 
and prevention of 
complications 
(Cacciotti, 2017). 
treatment of sickle 
cell disease pain and 
may contribute to 
optimal and consistent 
care 
 Pediatric emergency 
department analgesic 
guidelines for sickle 
cell disease pain are 
not universal. 
 Pain description: mild 
scale 1-3; moderate 
scale 4-6; severe scale 
7-10 
 Categories of 
analgesics: narcotics-
morphine, Dilaudid, 
Percocet, or 
oxycodone 
Non-steroidal-
ibuprofen, ketorolac  
Combination-
NSAIDS and 
narcotics 
 Sickle cell pain 
encompasses both 
inflammatory and 
infarction and tissue 
damage. 
 In the pediatric 
emergency 
department for further 
pain management. 
 Improved pain 
management may 
help prevent 
hospitalizations 
and morbidity 
associated with 
sickle cell disease 
pain. 
 Optimal 
pharmacological 
intervention 
should aim at 
targeting both the 
inflammation and 
tissue damage 
components of the 
pain to optimize 
treatment. 
 Combination 
therapy may 
contribute to 
optimizing pain 
management in 
the emergency 
department. 
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emergency 
department 20% of 
adult trained 
physicians and 9% of 
pediatric trained 
physicians report 
utilizing protocols 
when managing sickle 
cell related pain. 
 
To determine if the 
length of hospital 
stay for an acute 
sickle cell disease 
pain event is 
impacted by time to 
initiation of first 
intravenous narcotic 
at presentation, total 
initial dose of 
opioids, and or time 
to initiation of first 
oral opioid 
(Brandow, 2016) 
Level 1: 
Systematic review 
of randomized 
controlled 
guidelines 
 Early initiation of oral 
opioids facilitates 
transition to home 
pain management 
regimen. 
 Higher initial dose of 
opioids during early 
management of pain 
associated with 
improved quality of 
life scores at 
discharge 
 Earlier initiation of 
oral opioids in 
patients hospitalized 
with an acute sickle 
cell disease painful 
crisis strongly 
associated with 
shorter length of stay 
and improved quality 
of life at discharge 
 Early initiation of 
oral opioid 
therapy could 
eventually lead to 
standardization of 
treatment 
protocols for 
sickle cell disease 
pain. 
 
 
Recommendations 
 Collectively the 
existing 
postoperative data 
and findings 
provide rationale 
for future 
prospective trials 
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regarding the 
effectiveness of 
early initiation of 
oral opioids. 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: 
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database searching 
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Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n =489) 
Records screened 
(n = 1,076) 
Records excluded 
(n =1,020) 
Full-text articles assessed 
for eligibility 
(n =56) 
Full-text articles excluded, 
with reasons 
(n = 35) 
Studies included in 
qualitative synthesis 
(n = 0) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 21) 
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